Jinfo BlogAnalyse and Visualise the Drug Development Cycle with Cortellis

Tuesday, 29th July 2014 Sign in to MyJinfo or create an account be able to star items Click for printable version Subscribe via RSS to get updates as soon as Blog items are added Tweet about this item on Twitter Share on Facebook Share on LinkedIn

By Yulia Aspinall

« Blog


The new Cortellis life sciences platform from Thomson Reuters will be welcomed by many in the current "merger mania" environment in biopharma, explains reviewer Yulia Aspinall.



The process of developing a new medicine is long and complex, with constant demands for different types of information from a variety of stakeholders in the process (scientific, clinical, legal and commercial, to name but a few).

Information professionals have a bewildering array of resources at their disposal to service this demand, both free and paid-for. Some of these provide access to a single type of information, for example Pubmed, and others to a variety of different types, such as Thomson Reuters' Cortellis.

Powered by Thomson Reuters Data

Cortellis is a new platform which  integrates data from many well-known Thomson Reuters databases, including Thomson Pharma, Integrity and IDRAC and also offers users some new and unique analytical tools.

One of these - Virtual Merger - has a "wow factor" which, in my view, could on its own provide justification for purchasing the product.

Visualise a Virtual Merger

Virtual Merger, powered by TIBCO Spotfire, does exactly what the name suggests, providing a visual representation of a "virtual merger" of two companies of the user's choice.

The tool is accessed from the Analyze portlet on the Cortellis homepage; after entering the names of  possible merging companies, users can view the visualised results  on a pop-up page with intuitive visualisations and analytics.

The data can be displayed by:

  • Development Funnels
  • Drugs by Therapy Area
  • Comparison by Action or Indication
  • Comparison by Development Status
  • Small Molecules vs Biologics
  • Consensus Mechanisms
  • Drug Financials
  • Overviews.

There are also multiple filters available to use, such as Indications, Actions, Development Status, Drugs and Companies to narrow down the comparison according to the requirements.

Making M&A Decision-Making Quicker and Easier

In the current "merger mania" environment in biopharma industry, this tool will be welcomed by many in the company, especially by business development and senior management.

With the ability to analyse and visualise large amounts of data in minutes, and hence save potentially substantial amounts of work during the M&A decision-making process, the potential for time and workload savings is clear and could make the purchase of the platform a rational business decision.

Editor's Note

Cortellis has a host of interesting features. The full FreePint Report: Product Review of Cortellis is now available in PDF format, in a convenient package for reference and sharing, for those with a FreePint Subscription.

This article is part of the FreePint Topic Series: Next-Generation Competitive Intelligence which ran from May-June 2014. Registration provides a free copy of the FreePint Report: Buyer's Guide on Competitive Intelligence.

« Blog

Benefit from our research

Content and Community

Connect your team with the practical tools, original research and expertise to build and support information strategy in your organisation.

A Jinfo Subscription gives access to all Content (articles, reports, webinars) and Community.

Subscription benefits


Our proven processes, resources and guidance will help your team make the shift from transaction centre to strategic asset.

Read case studies, and start the conversation.

Consulting benefits